Corporate Social Responsibility: Corporate Governance and Business Ethics

We deliver integrity and innovation to create better health.

  • Corporate Governance & Business Ethics

    Go To:

    About McKesson
    Our work, at every level and in every role, is driven by our ICARE and ILEAD shared principles.

    Compliance and Integrity
    Integrity is a key principle that informs how we make decisions and take actions every day. It’s mandatory at McKesson.

    Public Affairs
    We view public policy engagement as an important strategy to address issues that affect our operations and those of our customers.

    McKesson's Response to the Opioid Crisis
    Learn how we're responding to the opioid epidemic.

    Supplier Diversity
    We have long-term relationships with the communities where we operate, and we're honored to contribute to those communities through our supplier diversity initiatives.

    Corporate Governance and the Board of Directors
    We're committed to sound and effective corporate governance practices.

    Stakeholder Engagement
    We regularly engage with stakeholder groups to understand concerns and issues, and gather their feedback.

    About This Report
    This corporate social responsibility report was prepared in reference to the Global Reporting Initiative's guidelines.

For businesses across healthcare, being healthy means having what you need to operate more efficiently and improve the lives of patients. McKesson champions those working on the front lines of healthcare by helping them deliver better care at lower costs. We deliver excellence. We deliver value. And we deliver for each other.

About McKesson HallAbout McKesson

Ranked #6 on the FORTUNE 500, McKesson is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care and healthcare information technology. We partner with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.

At the end of FY18, McKesson had approximately 70,000 employees and generated revenues of $208.4 billion.

ICare Shared PrinciplesOur ICARE and ILEAD Shared Principles

Our work, at every level of McKesson and in every role, is driven by our shared principles, known as ICARE (integrity, customer-first, accountability, respect and excellence) and ILEAD (inspire, leverage, execute, advance and develop).

These principles unite our employees, connecting us across business units, locations and functional areas. Living out these values is what shapes the corporate culture at McKesson. It’s what enables us to make a positive difference in the world.

We see examples of ICARE and ILEAD every day, at every McKesson location. These principles particularly come to light when our employees work together to make a difference for customers and patients — and even save a life, as in the story below.

Awards During FY17

McKesson had the honor of receiving a number of significant awards over the past fiscal year.

Fortune Logo

Recognizes McKesson’s achievement in the nine attributes of reputation: innovation, people management, use of corporate assets, social responsibility, quality of management, financial soundness, long-term investment value, quality of products/services and global competitiveness.

JD Power

Based on responses from nearly 15,000 pharmacy customers who filled a new prescription or refilled a prescription during the three months prior to the survey period of June 2016. Key factors assessed include the store, cost competitiveness, non-pharmacist staff and pharmacist.

Military Friendly

Criteria include veteran hiring, advancement and retention, culture, policies and compliance, and recruiting and sourcing.

Human Rights Campaign

Recognizes McKesson’s 100% score on the Corporate Equality Index, a benchmarking tool on corporate policies and practices pertinent to lesbian, gay, bisexual and transgender employees.

Black Enterprise

2016 Best Companies for Diversity

Criteria include percentage of African-Americans and members of other ethnic minority groups represented in a given company’s workforce, senior management positions and board of directors, and percentage of total procurement dollars spent with companies owned by African-Americans and members of other ethnic minority groups.

EGR and Council

Honors McKesson’s national employee resource group structure for advancing the diversity and inclusion process and demonstrating results in our workforce, workplace and marketplace.


McKesson Real Estate was honored for its use of technology, innovative end-to-end process design, and a white paper written in partnership with Stanford University’s Center for Integrated Facilities Engineering.

Compliance and Integrity

McKesson’s corporate character and all that we do, from the boardroom to the distribution center floor, are defined by our ICARE shared principles. Integrity (“I”) is a key principle that informs how we make decisions and take actions every day; it’s mandatory at McKesson.

Code of ConductMcKesson’s strength and reputation are rooted in high standards of business conduct driven by these principles, which extend to our relationships with our customers, suppliers and shareholders. To uphold these high standards and maintain our culture of integrity, we have a Board-approved Code of Conduct and a comprehensive Compliance and Ethics program. Our Code of Conduct, which we have translated currently into 13 languages and dialects, applies globally to all employees, officers and directors. The Code describes fundamental principles, policies and procedures that shape our work and provides each of us with guidance to make appropriate decisions when we are faced with ethical issues.

Comprehensive Compliance and Ethics Program

McKesson has established a comprehensive Compliance and Ethics program integrated throughout the company and our various business units. Our General Counsel is the Chief Compliance Officer for the Corporation, aided by a Compliance, Regulatory & Ethics group within the General Counsel Organization and Business Unit Compliance Officers embedded within the operating business units. The Chief Compliance Officer oversees and monitors implementation of the program, which encompasses standards and guidelines set out by regulators, including the Office of the Inspector General (OIG) of the U.S. Department of Health and Human Services. Our compliance program includes:

  • Written and publicized policies and procedures
  • Compliance communications and web resources
  • Regulatory and compliance training
  • Internal auditing and compliance monitoring
  • A toll-free Integrity Line
  • Investigations relating to regulatory, compliance and ethics matters
  • Where necessary, corrective and/or preventative action

A training program that combines both interactive online and in-person training helps ensure that our employees are familiar with our Code of Conduct and company policies. Areas covered by this training program include the Code of Conduct, fraud and abuse laws, sexual harassment, anti-retaliation, HIPAA and patient privacy, anti-corruption, antitrust and trade regulation laws, environmental health and safety, and other important regulatory and compliance topics.

Integrity LineIntegrity Line

The McKesson Integrity Line is available 24 hours a day, 7 days a week. It allows employees to raise concerns (anonymously if they wish), including possible violations of McKesson policies or other illegal or unethical activity. An independent third-party provider answers and documents all calls before forwarding them to McKesson. We investigate all allegations and provide reports of allegations and investigations to senior management and the Audit Committee of the Board of Directors.

In addition to the Integrity Line, employees are encouraged to contact the Compliance, Regulatory and Ethics group; their Business Unit Compliance Officer; the HR Support Center; the Law Department; or their supervisor with any questions or concerns they may have regarding our compliance program or potential compliance concerns, company policies and procedures, or the proper course of action in a particular situation. Retaliation against an employee who makes a good faith complaint through the Integrity Line or other channels is strictly prohibited at McKesson.

Following an investigation, we may take corrective actions as warranted by the situation, including disciplinary action or retraining. Ultimately, it is every employee’s responsibility to ensure that we as a company comply with the many laws, regulations and ethical standards affecting our business.

Our Commitment to Responsible Marketing

Responsible MarketingMcKesson sees the way we market our products and services as an opportunity to demonstrate good corporate citizenship. The promotion, marketing and sale of drugs, medical devices and other medical technologies are subject to diverse legal and ethical standards. We respect the integrity of the relationship between patients and providers, and the healthcare decisions they make. We also believe that anyone who pays for healthcare goods and services should get full value for their purchases. McKesson is committed to complying with applicable laws and regulations that protect against fraud, waste and abuse in healthcare. We adhere to ethical standards in conducting our marketing and promotional activities. Our employees are regularly trained on our Code of Conduct and other company policies, such as the U.S. Sales and Marketing Policy, which make clear our commitment to market and sell honestly.

Our Commitment to our Government Customers

As one of the nation’s largest government contractors, McKesson is proud to partner with our government customers in meeting the healthcare needs of veterans, members of our military, children and disadvantaged populations. McKesson recognizes that our government customers face unique challenges and obligations and we are dedicated to satisfying our customers. McKesson’s Compliance and Ethics program is critical to successfully performing our government contracts. We strive to meet our customers’ expectations and to correct any shortcomings in our performance.

Our Anti-Corruption Policies

Our business is increasingly global. We recognize the importance of demonstrating strong ethics and corporate citizenship in the global economy. McKesson prohibits bribery and other forms of corruption in our business, and we continue to refine and enhance our programs to prevent corruption. We have developed clear and specific policies, including a Global Anti-Bribery Policy, to guide appropriate decision-making with regard to gifts, meals and entertainment, and interactions with government officials, among other things.

Our Anti-Slavery Policies

McKesson is committed to good corporate citizenship and the highest ethical standards. To fulfill these standards, we take steps to ensure that slavery and related human trafficking do not form part of the supply chain, consistent with the UK Modern Slavery Act.

Public AffairsPublic Affairs

Our businesses and customers span all settings of healthcare, which allows us to understand our complex health system in a uniquely comprehensive way. At McKesson, we view public policy engagement as an important business strategy to proactively address issues that affect our operations as well as those of our customers, including physician groups, pharmacies, hospitals, manufacturers, homecare agencies and long-term care providers.

Whether it is an election year or not, our public policy efforts focus on supporting our businesses and advocating constructive policy solutions to challenging and relevant healthcare issues. We help educate government officials at the local, state and federal levels as they develop policies to improve the healthcare delivery system. Learn more about McKesson's public policy approach in the U.S.

In this section, we also describe association memberships, as specified in the Global Reporting Initiative’s guidelines. At the end, we have a list of association memberships specific to Canada.

Selected Public Policy Engagement

McKesson supports healthcare policies that promote the safe, cost-effective and timely distribution of pharmaceuticals and medical supplies, as well as the use of innovative health information technology solutions that improve the efficiency, cost savings and quality of care. We engage on issues such as the security of the supply chain and the future of healthcare reform.

One of our areas of policy engagement is the opioid crisis. The U.S. is suffering from a dangerous and growing opioid epidemic which affects lives, families, jobs and productivity every day. This multi-faceted problem must be addressed through a comprehensive approach that includes the doctors who write the prescriptions, the pharmacists who fill them, the distributors who fill and deliver pharmacies’ orders, the manufacturers who make and promote the products and the regulators who license the above activities and determine supply.

McKesson is fully committed to working with all stakeholders to protect the supply chain and prevent diversion while ensuring service to patient needs. With a broad view of healthcare and customers across industry and government, McKesson is uniquely positioned to advocate for a comprehensive set of policy and business solutions that could significantly slow the abuse and diversion of opioids, to the benefit of patients and their families. In April 2018, we released our latest set of policy recommendations focused on enhancing clinical knowledge and using data and technology solutions to fight the opioid epidemic. (This new policy paper expands upon our March 2017 recommendations.) To learn more about all that McKesson is doing to help address the opioid crisis, please visit McKesson: Fighting Opioid Abuse.

Stakeholder Engagement

McKesson’s Public Affairs activities aim to shape health policy, create productive collaborations with key internal and external stakeholders and enable McKesson to become a trusted advisor on many healthcare policy issues and other tax, trade, labor, environmental and general business climate issues that affect our ability to satisfy our mission. We engage stakeholders in various ways in these areas:

  • Government Relations: We continue to develop and strengthen relationships with public officials at all levels of government as we advocate policies to improve healthcare delivery and promote efficiency. McKesson retains contract lobbyists in Washington, D.C., and in selected states to provide additional insight into legislative issues as well as regulatory initiatives, and to help McKesson proactively shape the outcome of these public policy issues.
  • Internal Subject Matter Experts: By collaborating with internal subject matter experts and coordinating our messages across the company, we develop policy solutions to challenging healthcare issues. The Public Affairs team leads selected task forces comprising employees from across the enterprise to focus on policy issues important to the company and strengthen and maximize our advocacy efforts at the federal, state and local levels. In conjunction with experts in our business, the Public Affairs team also coordinates corporate strategies on regulatory issues of importance to McKesson, increases intra-company awareness of regulatory issues and ensures a coherent and substantive company-wide position on critical public policies.
  • Industry Partners and Policymakers: McKesson plays an active role in educating policymakers about the solutions we offer to improve patient safety, reduce the cost and variability of care, and improve the quality and efficiency of healthcare delivery. Through tours of our distribution centers and visits to pharmacy and hospital customers, policymakers can better understand the steps we take to assure the safe, efficient and rapid distribution of pharmaceuticals and medical-surgical supplies, as well as the tools and technology solutions we provide our customers to improve the quality and delivery of healthcare.
Employee Civic EngagementEmployee Civic Engagement

McKesson supports the civic engagement of our employees through a variety of activities. Our employee engagement programs empower McKesson’s U.S. employees to engage on public policy issues that affect McKesson, our customers and the patients we serve. We support employee civic engagement in these ways:

  • Voting: During election years, our “get out the vote” effort provides official voter information to employees about state and federal elections, including how to register to vote, polling locations and important deadlines.
  • Employee Engagement: McKesson’s Advocacy Network program includes a website that provides information and resources on public policy, legislative process and civic engagement, monthly e-newsletters featuring legislative updates, policy analysis and election coverage and webinars on timely public policy issues and election analysis. Thousands of employees tune in to the quarterly webinars.
  • Employee Advocates: McKesson’s Advocacy Ambassadors are a subset of specially trained employees who are part of the extended Public Affairs team and serve as primary partners in the field with federal, state, or local level elected officials and as part of a broader community of influencers.
Political Engagement

McKesson understands that the decisions made by policymakers have a profound impact on our industry, business, customers and the patients they serve. We seek to educate elected and appointed officials about the solutions we offer to improve patient safety, reduce the cost and variability of care and improve the quality and efficiency of healthcare delivery.

McKesson believes that transparency and accountability with respect to political expenditures are important. In 2017, McKesson increased its disclosure of corporate political contributions to state and local candidates, parties, committees, ballot measures and political organizations, which is now posted publicly. The company also discloses annual payments to health policy, industry and/or trade organizations in excess of $50,000. View this information and review McKesson’s policy regarding political contributions on our company website.

McKesson’s Response to the Opioid Crisis

The opioid epidemic is a public health crisis, and we take our responsibility to help manage the safety and integrity of the pharmaceutical supply chain extremely seriously.

Over the past decade, as the epidemic evolved rapidly, we made a commitment to strengthen our processes, technology and human resources dedicated to preventing diversion. We aggressively work to help prevent the diversion and abuse of prescription opioids through our innovative supply chain security programs and proactive order monitoring initiatives, while ensuring appropriate treatments are available to patients. We are fully committed to working with all stakeholders to develop a public policy response to this evolving epidemic.

McKesson has invested millions of dollars to build a Controlled Substance Monitoring Program (CSMP) that monitors suspicious ordering patterns, blocks the shipment of controlled substances to pharmacies when certain thresholds are reached, reports suspicious orders to the DEA and educates our customers on identifying opioid abuse. Today, we believe we have a best-in-class CSMP and are dedicated to ongoing enhancements.

Some of our actions over the last four years include:

  • Expansion of our compliance team: In order to further strengthen our compliance program, McKesson added a number of diversion experts to its CSMP team, which now includes 40+ individuals with more than 240 years of cumulative DEA enforcement experience. McKesson has also hired industry experts with experience in the retail pharmacy industry, state and board of pharmacy investigators, pharmaceutical manufacturers, and data analytics. McKesson believes that our current CSMP team is among the strongest in the industry.
  • Customer due diligence: McKesson performs comprehensive due diligence on prospective pharmacy customers before agreeing to supply medications. This rigorous diligence process includes the gathering of specific pharmacy information and the validation of regulatory licensure.
  • Ongoing oversight: McKesson monitors its customers’ orders of controlled substances for potential diversion throughout the customer relationship. As part of its review process, pharmacies are subject to a complete due diligence analysis, pursuant to McKesson’s proprietary CSMP. McKesson reports all controlled substances transactions to the Drug Enforcement Administration (DEA), including those deemed suspicious by our CSMP.
  • Advanced threshold analytics capabilities: McKesson has expended significant resources to develop and refine a cutting-edge controlled substances threshold management program, using complex and dynamic data analytics.
  • Physical supply chain: Controlled substances are locked, monitored and stored in two DEA-regulated spaces. Schedule 2 narcotics go in a high-security “vault” and inventory checks of controlled substances are conducted frequently. Formal background checks are given to all employees who handle Schedule 2 narcotics. Controlled substances are packaged under video cameras, where they’re packed in specially sealed plastic bags. Unmarked trucks are used in the delivery of the medications McKesson distributes.
  • Customer education: McKesson has been proactive in educating its customers about the importance of compliance with DEA and state agency regulations. McKesson provides its customers with literature on how to identify the warning signs of prescription abuse and diversion. McKesson conducts informational meetings for customer groups and makes presentations at annual trade shows and pharmacy association meetings to emphasize the importance of preventing diversion. Similarly, McKesson educates its own employees on the company’s regulatory obligations, including CSMP-specific training sessions at annual sales meetings.
  • Ongoing state and federal collaboration efforts: McKesson is an active participant in legislative efforts around controlled substances. The company also strongly supports the Center for Disease Control’s clinical guidelines and calls for additional formal and continuing medical education on the dangers of opioid use as important ways to curb clinically inappropriate prescribing, doctor shopping and diversion.
McKesson’s Opioid Task Force

In an effort to use McKesson’s vast and unique position within the healthcare landscape to identify potential solutions to the opioid crisis, McKesson created an internal task force in 2015 to further study the opioid issue and its challenges. The task force was comprised of McKesson subject matter experts, including clinicians, all of whom had a strong understanding of the problems and players in the opioid management ecosystem.

During FY17, our task force proactively developed a policy paper, which includes recommendations that we are actively sharing with federal and state elected officials and other stakeholders across the healthcare supply chain. Our recommendations include program and policy changes that encourage industry participants to work together to:

  • Use data analytics and technology to control the risks of overprescribing
  • Better utilize clinical-based practice guidelines
  • Provide real-time accessible information to pharmacists prior to dispensing opioids
  • Identify patients most at risk
  • Improve information sharing among different monitoring programs and
  • Partner with academic organizations / private sector to develop data-based solutions

To learn more, see our policy paper, “Combating the Opioid Abuse Epidemic.”

Minority SuppliersSupplier Diversity

McKesson is committed to expanding opportunities to businesses that can provide exceptional service at a competitive value and cost. We have long-term relationships with the communities in which we work, live and do business, and we are honored to contribute to those communities through our supplier diversity initiatives. We started our formal supplier diversity program in 1993. Over the past five years, our number of minority suppliers has increased 91%.


Minority Supplier


At McKesson, diversity efforts are led by senior management, who hold themselves and their teams accountable for success. The goal of our leaders is to advance inclusion at all levels of our company and in all our activities.

Lance Dorsey Quote“At McKesson, diversity within our supply chain isn’t a box to check or an accolade for our website,” says Lance Dorsey, senior manager, Supplier Diversity. “For us, supplier diversity means something more. We recognize that small and diverse businesses offer agile solutions to meet our business needs. Small businesses employ people from the communities we serve and help sustain our valued customer relationships. Additionally, we partner with small diverse suppliers who we truly believe share our vision and partner to make that vision a reality.”

McKesson’s leadership believes that diverse and small businesses are vital business partners. The company supports a strong outreach strategy to ensure that qualified small and diverse businesses are given a fair opportunity to provide products and services to our company. McKesson maintains memberships in and/or actively supports the following organizations:

Corporate Governance and the Board of Directors

Our Board of Directors values the views of our shareholders and believes regular communication throughout the year not only is a testament to good governance, but also fosters accountability.

We aim to ensure that our shareholders feel confident they have a voice in our board room. The McKesson Board of Directors takes shareholders' views into account, both in terms of our governance today and also long into the future. For example, in 2017 McKesson has updated our political contributions policy to include additional Board oversight and public disclosure of our corporate political contributions on our company website. In addition, the Board announced its decision to split the role of chairman and CEO in the future, commencing with the company's next CEO. The Board will continue its practice of evaluating at least annually whether its leadership structure continues to be in the best interest of the company and its shareholders.

Between the 2016 and 2017 Annual Meetings, we engaged with institutional investors and pension funds representing more than 60% of the company's outstanding common stock. We believe listening to the views of our shareholders will continue to be the cornerstone of our governance practices and in the best interest of our Board, the company and stakeholders.

Our Board diligently exercises its oversight responsibilities with respect to the company's business and affairs consistent with the highest principles of business ethics and corporate governance requirements of federal law, state law and the NYSE. We highlight these practices below.

Key Governance Attributes


Strong Role for Lead Independent Director

Initially established in 2013, the role of Lead Independent Director has a robust set of duties and authorities under our Corporate Governance Guidelines. Details of this role are provided below.

Leading on Board Diversity

One-half of McKesson’s 2017 director nominees are diverse. Since 2002, women have held 3 of our Board’s seats which represents one-third of our current nominees.

Annual Director Performance Evaluation

The Lead Independent Director conducts the performance evaluation of all Board members.

Annual CEO Succession Review

The Board is responsible for approving and maintaining a succession plan for the CEO and other executive officers. The annual CEO succession review is led by the Lead Independent Director and held in executive session of the full Board.

Leading on Proxy Access

A shareholder or shareholder group holding at least 3% of the company’s stock for at least 3 years may include in McKesson’s proxy materials director candidates to fill up to 20% of available Board seats.

Shareholder Right to Call a Special Meeting

A By-Law amendment in 2013 established the right to call a special meeting of stockholders, for record holders who have held a net long position of at least 25% of the company’s outstanding shares for at least 1 year.

Disclosure of Political Contributions

McKesson believes that transparency and accountability with respect to political expenditures are important. Beginning in 2017, McKesson voluntarily discloses corporate political contributions and trade associations to which payments exceed $50,000. The company also prohibits trade organizations from using corporate dollars for political purposes.

Risk Oversight

The Board as a whole and its committees devote significant time and effort to understanding and reviewing enterprise risks. This includes oversight of our company’s reputation as well as review of risks related to financial reporting, compensation practices, and cybersecurity.

Global Code of Conduct

McKesson’s Code of Conduct, which describes fundamental principles, policies and procedures that shape our work and help our employees, officers and directors make ethical decisions, has been adapted and translated to apply throughout our global presence.

Corporate Governance Guildlines

McKesson’s Corporate Governance Guidelines address various governance matters, consistent with NYSE listing requirements, including: director qualification standards; access to management and independent advisors; compensation; director orientation and continuing education; and management succession.

Independent Board

All directors, with the exception of Mr. Hammergren, are independent, consistent with NYSE requirements and our Corporate Governance Guidelines.

Other Investor-Friendly Practices

  • Eliminated “poison pill”
  • Eliminated supermajority voting requirements
  • Majority voting standard for uncontested director elections
  • Declassified Board

Our Board's commitment to diversity and inclusion: Diversity is important to our Board; currently, one-half of our Board seats are held by women and people of color. Our Board of Directors and management team have a long track record of advancing diversity throughout the organization. This record includes the creation of a diversity and inclusion organization more than ten years ago, followed shortly thereafter by the appointment of our first Chief Diversity Officer. Our Board of Directors routinely receives reports from management on McKesson’s diversity and inclusion efforts. Learn more about McKesson's diversity and inclusion efforts.

Board oversight and review of sustainability and corporate responsibility practices: We recognize the increasing focus and importance surrounding environmental sustainability disclosure, and we have proactively taken steps to provide our shareholders with insight into our environmental sustainability efforts. In our 2017 Proxy Statement and Supplemental Proxy Statement materials, McKesson disclosed an update on our environmental sustainability efforts; these materials were publicly filed with the U.S. Securities and Exchange Commission (SEC). In 2017, the Board also approved amendments to our Corporate Governance Guidelines to make clear that the Board has oversight of and review the company's sustainability and corporate responsibility practices.

Women on Boards

Detailed information about our corporate governance practices, including our by-laws, Corporate Governance Guidelines and directors’ biographies, is available on our company website.

Shareholders and other interested parties may communicate with any of our directors, including the Lead Independent Director, by addressing their correspondence to the Board member (or members) at:

c/o the Corporate Secretary’s Office
McKesson Corporation
One Post Street
San Francisco, CA 94104

Email: or

Shareholders may also submit proposals to be voted on, if properly presented, at the company’s annual meeting of shareholders. Additional details on how to submit a proposal are available in the company’s annual proxy statement that is filed with the SEC. The proxy statement is available on our corporate website as well as the SEC website. We typically announce preliminary voting results at the annual meeting of shareholders, followed shortly by the announcement of final voting results in a current report on Form 8-K that is filed with the SEC.

Stakeholder EngagementStakeholder Engagement

As a company, our impact encompasses employees, customers, investors, partners, governments and communities. We engage with all of these stakeholder groups to understand concerns and issues, and gather their feedback. We also engage with internal business leaders, both through the reporting process and via our Corporate Social Responsibility Advisory Council.

In FY18, McKesson is conducting a formal materiality analysis to systematically assess and prioritize corporate social responsibility (CSR) topics. Through this analysis, we will help ensure that our CSR reporting and internal initiatives are aligned with what is most important to our business and our stakeholders.

In interacting with our stakeholders, we have identified several corporate social responsibility topics not addressed elsewhere in this report:

  • Use of Medicines for Lethal Injections: McKesson has contractual arrangements with some manufacturers that restrict the sale of certain medicines to certain customers, such as prison systems and others, for lethal injections. McKesson is committed to helping manufacturers implement their policies in this area. The needs and requirements of manufacturers vary; therefore, our contractual commitments, controls and processes also vary by manufacturer. McKesson has processes and systems to enable manufacturers to validate McKesson’s performance against our contractual arrangements.
  • Principles for a Sustainable Supply Chain: When we onboard suppliers outside the U.S., we require they agree to McKesson’s Sustainable Supply Chain Principles (MSSP). The MSSP covers areas including:
    • Worker protection from hazards at the workplace and in any company living quarters
    • Emergency preparedness at the workplace and in any company living quarters
    • Programs to identify hazards and manage occupational risk
    • Complying with applicable legal regulations for environmental protection
    • Systems and procedures to prevent accidental spills

    In the U.S., we address these areas through our compliance with federal and state legislation.

  • Animal Testing: McKesson does not perform animal testing, nor do we contract it out. We do not own molecules. Our role in clinical trials is to provide services to physicians to access clinical trials for humans.
About This Report

This report details McKesson’s CSR efforts during FY17 (April 1, 2016 – March 31, 2017). The report is an annual publication. The previous FY16 report was published in September 2016.

McKesson is headquartered in San Francisco, California. During FY17, most of McKesson’s annual revenue was generated in North America. While the scope of the FY17 report primarily reflects North America, our business description, ethics and governance sections reflect companywide practice, and we have expanded carbon emissions reporting to include McKesson Europe data. McKesson Europe, along with McKesson Canada and U.S. business units, is also part of our Community Heroes employee recognition program. This expansion of scope began with our FY16 report.

For more information about McKesson’s operations, including joint ventures, subsidiaries, leased facilities, outsourced operations and other entities that can significantly affect comparability, please refer to the FY17 10-K, McKesson’s Annual Report.

The Global Reporting Initiative (GRI) G4 Guidelines, internationally recognized sustainability and social responsibility reporting standards, help frame the information within this report. We have created this report in reference to the “Core” version of the guidelines, along with Specific Standard Disclosures identified as material. For additional questions about the report, please send an email to

  • Contact Us

    Whether you have a question or just want to learn more about social responsibility at McKesson, we look forward to hearing from you.